Abstract:Hotspot mutations in the NRAS gene are causative genetic events associated with the development of melanoma. Currently, there are no FDA-approved drugs directly targeting NRAS mutations. Previously, we showed that p38 acts as a tumor suppressor in vitro and in vivo with respect to NRAS-mutant melanoma. We observed that because of p38 activation through treatment with the protein synthesis inhibitor, anisomycin leads to a transient upregulation of several targets of the cAMP pathway, representing a stressed cancer cell state that is often observed by therapeutic doses of MAPK inhibitors in melanoma patients. Meanwhile, genetically induced p38 or its stable transduction leads to a distinct cellular transcriptional state. Contrary to previous work showing an association of invasiveness with high p38 levels in BRAF-mutated melanoma, there was no correlation of p38 expression with NRAS-mutant melanoma invasion, highlighting the difference in BRAF and NRAS-driven melanomas. Although the role of p38 has been reported to be that of both tumor suppressor and oncogene, we show here that p38 specifically plays the role of a tumor suppressor in NRAS-mutant melanoma. Both the transient and stable activation of p38 elicits phosphorylation of mTOR, reported to be a master switch in regulating autophagy. Indeed, we observed a correlation between elevated levels of phosphorylated mTOR and a reduction in LC3 conversion (LCII/LCI), indicative of suppressed autophagy. Furthermore, a reduction in actin intensity in p38–high cells strongly suggests a role of mTOR in regulating actin and a remodeling in the NRAS-mutant melanoma cells. Therefore, p38 plays a tumor suppressive role in NRAS-mutant melanomas at least partially through the mechanism of mTOR upregulation, suppressed autophagy, and reduced actin polymerization. One or more combinations of MEK inhibitors with either anisomycin, rapamycin, chloroquine/bafilomycin, and cytochalasin modulate p38 activation, mTOR phosphorylation, autophagy, and actin polymerization, respectively, and they may provide an alternate route to targeting NRAS-mutant melanoma.

The Pathways to Tumor Suppression Via Route P38

Major Physiological Signaling Pathways in the Regulation of Cell Proliferation and Survival

The HBP1 Transcriptional Repressor and the P38 MAP Kinase: Unlikely Partners in G1 Regulation and Tumor Suppression

A novel function of p38-regulated/activated kinase in endothelial cell migration and tumor angiogenesis

p53 signaling and autophagy in cancer: a revolutionary strategy could be developed for cancer treatment.

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting

p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents.

Signal integration by JNK and p38 MAPK pathways in cancer development

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis

Targeting p38γ to inhibit human colorectal cancer cell progression.

Role of p38 MAP kinase in cancer stem cells and metastasis

Elucidating the chain of command: our current understanding of critical target genes for p53-mediated tumor suppression

Progress and Prospects: Roles of P53 in Tumor Development

Functions of P38 Mitogen-Activated Protein Kinase Alpha and Beta in Human Pancreatic Cancer Cells

Mutant P53 Promotes Tumor Cell Malignancy by Both Positive and Negative Regulation of the Transforming Growth Factor Β (Tgf-Β) Pathway.

A Different Facet of p53 Function: Regulation of Immunity and Inflammation During Tumor Development

P38 Mediates Tumor Suppression through Reduced Autophagy and Actin Cytoskeleton Changes in NRAS-Mutant Melanoma

TP53, TP53 Target Genes (DRAM, TIGAR), and Autophagy.

PPM1G promotes the progression of lung adenocarcinoma by inhibiting p38 activation via dephosphorylation of MEK6

Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies